Recifercept

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

22 competitors in Achondroplasia

#DrugCompanyPhaseTrials

1

Recombinant Human Growth Hormone

Changchun GeneScience Pharmaceutical Co., Ltd.

Approved

12

BMN 333

BioMarin Pharmaceutical

Phase 3

63

Voxzogo

BioMarin Pharmaceutical

Phase 2

24

Truseltiq

HHelsinn Healthcare SA

Phase 2

15

TYRA-300

TTyra Biosciences, Inc

Phase 2

16

Yuviwel

Ascendis Pharma

Phase 2

27

SAR442501

Sanofi

Phase 2

—8

Infigratinib /kg

QQED Therapeutics, a BridgeBio company

Phase 2

29

Genotropin

EMD Serono

Preclinical

110

Transcon CNP

AAscendis Pharma Growth Disorders A/S

Phase 2

4Show 2 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Achondroplasia2 trials

Continuation Study of Long-term Safety, Tolerability, Pharmacokinetics and Efficacy of Recifercept in Achondroplasia

Terminated·Pfizer·Phase 2·NCT05116046·35 enrolled

A Study Of Safety, Tolerability And Effectiveness Of Recifercept In Children With Achondroplasia

Terminated·Pfizer·Phase 2·NCT04638153·60 enrolled

Tics1 trial

Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Recifercept in Healthy Chinese Participants

Withdrawn·Pfizer·Phase 1·NCT05061277

Unspecified1 trial

Study To Evaluate The Pharmacokinetic, Safety And Tolerability Of Single Or Multiple Subcutaneous Doses of Recifercept

Completed·Pfizer·Phase 1·NCT04543344·24 enrolled

Details

Drug Info

Related News